Home › Compare › DGNG vs MRK

DGNG vs MRK: Dividend Comparison 2026

DGNG yields 28571.43% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DGNG wins by $1.8174438113797412e+21M in total portfolio value
10 years
DGNG
DGNG
● Live price
28571.43%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8174438113797412e+21M
Annual income
$1,805,016,220,998,010,500,000,000,000.00
Full DGNG calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — DGNG vs MRK

📍 DGNG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDGNGMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DGNG + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DGNG pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DGNG
Annual income on $10K today (after 15% tax)
$2,428,571.43/yr
After 10yr DRIP, annual income (after tax)
$1,534,263,787,848,309,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, DGNG beats the other by $1,534,263,787,848,309,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DGNG + MRK for your $10,000?

DGNG: 50%MRK: 50%
100% MRK50/50100% DGNG
Portfolio after 10yr
$908721905689870598144.00M
Annual income
$902,508,110,499,005,300,000,000,000.00/yr
Blended yield
99.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DGNG
No analyst data
Altman Z
-0.4
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DGNG buys
0
MRK buys
0
No recent congressional trades found for DGNG or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDGNGMRK
Forward yield28571.43% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$1.8174438113797412e+21M$56.8K ✓
Annual income after 10y$1,805,016,220,998,010,500,000,000,000.00 ✓$9,798.13
Total dividends collected$1.816625906206534e+21M$28.9K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DGNG vs MRK ($10,000, DRIP)

YearDGNG PortfolioDGNG Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,867,843$2,857,142.86$11,206$366.19+$2.86M → DGNG
2$768,847,726$765,779,134.08$12,650$502.35+$768.84M → DGNG
3$192,691,632,776$191,868,965,708.97$14,407$694.19+$192691.62M → DGNG
4$45,147,257,398,343$44,941,077,351,272.53$16,585$967.82+$45147257.38M → DGNG
5$9,889,057,995,779,864$9,840,750,430,363,638.00$19,342$1,363.89+$9889057995.76M → DGNG
6$2,025,084,628,942,200,600$2,014,503,336,886,716,000.00$22,913$1,947.19+$2025084628942.18M → DGNG
7$387,709,524,857,534,600,000$385,542,684,304,566,450,000.00$27,662$2,823.89+$387709524857534.63M → DGNG
8$69,399,422,486,233,860,000,000$68,984,573,294,636,305,000,000.00$34,159$4,173.35+$69399422486233856.00M → DGNG
9$11,614,570,450,215,628,000,000,000$11,540,313,068,155,356,000,000,000.00$43,337$6,308.80+$11614570450215628800.00M → DGNG
10$1,817,443,811,379,741,200,000,000,000$1,805,016,220,998,010,500,000,000,000.00$56,776$9,798.13+$1.8174438113797412e+21M → DGNG

DGNG vs MRK: Complete Analysis 2026

DGNG — Stock

Diguang International Development Co., Ltd. engages in the design, production, and distribution of small to medium-sized light emitting diode and cold cathode fluorescent lamp backlights primarily for large and medium sized companies. The company offers backlights for liquid crystal displays in various applications, such as color displays for cell phones, car televisions and navigation systems, digital cameras, televisions, computer displays, camcorders, PDAs, DVDs, CD and MP3/MP4 players, and appliance displays, as well as for indoor and outdoor lighting, and home and office use. It sells its products to customers primarily in Taiwan, Hong Kong, North America, Europe, Japan, Southeast Asia, and China Mainland. The company was founded in 2004 and is headquartered in Shenzhen, the People's Republic of China. Diguang International Development Co., Ltd. is a subsidiary of Sino Olympics Industrial Limited.

Full DGNG Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DGNG vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DGNG vs SCHDDGNG vs JEPIDGNG vs ODGNG vs KODGNG vs MAINDGNG vs JNJDGNG vs ABBVDGNG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.